|Mr. Ram Mukunda||Pres, CEO & Director||461k||N/A||1959|
|Ms. Claudia Grimaldi||VP & Principal Financial Officer||173k||N/A||1971|
|Mr. Rohit Goel||Mang. & Principal Accounting Officer||N/A||N/A||1994|
|Mr. Shajy Mathilakathu||Co-Principal Financial & Accounting Officer||N/A||N/A||1968|
|Dr. Jagadeesh Rao||Scientific Officer||N/A||N/A||1967|
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
India Globalization Capital, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.